{
  "name" : "dacemirror.sci-hub.se_journal-article_73abb9e0662b6ed35516ab20b7a3d426_xiao2019.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "An erythrocyte membrane coated mimetic nano-platform for chemo-phototherapy and multimodal imaging",
    "authors" : [ "Feng Xiao", "Jialong Fan", "Chunyi Tong", "Chang Xiao", "Zhou Wang", "Bin Liu", "Muhammad Daniyal" ],
    "emails" : [ "binliu2001@hotmail.com;", "wangwei402@hotmail.com" ],
    "sections" : [ {
      "heading" : null,
      "text" : "RSC Advances\nPAPER\nO pe\nn A\ncc es\ns A\nrt ic\nle . P\nub lis\nhe d\non 0\n4 Se\npt em\nbe r\n20 19\n. D ow\nnl oa\nde d\non 9\n/1 6/\n20 19\n8 :5\n3: 01\nA M . T hi s ar tic le is li ce ns ed u nd er a C re at iv e C om m on s A ttr ib ut io nN on C om m er ci al\n3 .0\nU np\nor te\nd L\nic en\nce .\nView Article Online View Journal | View Issue\nAn erythrocyte m\naCollege of Biology, Hunan University, binliu2001@hotmail.com; Fax: +86-731-897 bTCM and Ethnomedicine Innovation & Innovative Materia Medica Research In University of Chinese Medicine, Chang wangwei402@hotmail.com † Electronic supplementary informa 10.1039/c9ra05867b ‡ These authors contributed to the work eq authors.\nCite this: RSC Adv., 2019, 9, 27911\nReceived 29th July 2019 Accepted 29th August 2019\nDOI: 10.1039/c9ra05867b\nrsc.li/rsc-advances\nThis journal is © The Royal Society of C\nembrane coated mimetic nanoplatform for chemo-phototherapy and multimodal imaging†\nFeng Xiao,‡a Jialong Fan,‡a Chunyi Tong,‡a Chang Xiao,a Zhou Wang,a Bin Liu, *a Muhammad Daniyal b and Wei Wang *b\nThe tumor variability and low efficiency associated with conventional chemical drugs provide an impetus to\ndevelop drug-carrying systems with targeted accumulation and controllable release behavior. Herein,\nDOX-loaded Prussian blue (PB) nano-composites are developed after coating with erythrocyte\nmembrane (EM) and modifying with folic acid (FA). In these nano-composites, PB nanoparticles mixture\nwith different shapes were adopted to improve the photothermal performance, which is highly helpful\nfor cancer photothermal ablation and controllable drug release. In addition, the nano-composites were\nendowed with high biocompatibility, immune evading capacity, pH-/photo-responsive release behavior,\nand markedly prolonged blood circulation time, which was reflected by a 99.6% cervical tumor growth\ninhibition value (TGI) in vivo. Meanwhile, they functioned as multimodal bioimaging agents for\nphotothermal, fluorescence, and photoacoustic imaging of tumors. The reported strategy can be applied\nfor personalized therapy of various tumors by modifying the tumor-targeting molecule on the surface of\nnanoparticles."
    }, {
      "heading" : "Introduction",
      "text" : "Cervical cancer is the most common cancer in women worldwide, and it remains the leading cause of cancer-related deaths.1 Until now, several kinds of strategies have been developed for cervical cancer therapy. Among them, surgery is the treatment of choice for early invasive cancer. In more advanced cases, the combination of radiation with chemotherapy is the current standard of care. In patients with disseminated disease, chemotherapy or radiation provides symptom palliation. However, the indiscriminate tendency to kill normal cells and the destruction of the systemic immune system by chemical and radiation therapy severely impact the patient's quality of life aer several treatments.2 Recently combinational therapy strategies based on nanomaterials have attracted wide attention for tumor therapy, due to the advantages of reducing the occurrence of the multi-drug resistance of tumor and the effective ability to deal with the “heterogeneity”\nChangsha, 410082, China. E-mail:\n20939; Tel: +86-731-89720939 Development International Laboratory, stitute, School of Pharmacy, Hunan sha, 410208, P. R. China. E-mail:\ntion (ESI) available. See DOI:\nually and should be regarded as co-rst\nhemistry 2019\nof cancer cells, etc.3–5 Among of them, photothermal therapy (PTT), which employs a photothermal agent and near-infrared laser (NIR) for combination therapy of nano-systems, has recently emerged as an alternative with high selectivity and extremely low trauma.6,7 In this strategy, indocyanine green (ICG) is the most commonly used agent for PTT.8 However, this agent suffers from self-aggregation in physiological uids, nonspecic binding to serum proteins and rapid clearance from blood circulation.9 In order to circumvent these limitations, several groups have used carbon and metal-based nanomaterials with good photothermal conversion efficiency in the NIR region for PTT with satisfying results for tumor ablation.10–12 However, the practical application of these photothermal agents including GO and CuS is still limited due to their unpredictable metabolic pathways and potential longterm accumulation toxicity in vivo.13–15 As one kind of metal– organic frameworks nanomaterials, Prussian blue nanoparticles (PB NPs) have been permitted by the U.S. Food and Drug Administration (FDA) for treating solid tumors.16 This kind of nanomaterial showed not only unparalleled advantages in drug-loading efficiency but also indicated excellent photothermal conversion efficiency in the NIR region, as well.17,18 Meanwhile, it can act as an emergent photoacoustic divergence agent using its strong optical absorption capacity in the NIR area. For example, Gu and Ye used carbon dots/PB NPs as optical nanoprobes for cancer cell imaging and photothermal conversion nano-formers for tumor PTT.19 In addition, PB–polyL-lysine (PLL) nanocomplex has been used as a highly efficient\nRSC Adv., 2019, 9, 27911–27926 | 27911\nO pe\nn A\ncc es\ns A\nrt ic\nle . P\nub lis\nhe d\non 0\n4 Se\npt em\nbe r\n20 19\n. D ow\nnl oa\nde d\non 9\n/1 6/\n20 19\n8 :5\n3: 01\nA M . T hi s ar tic le is li ce ns ed u nd er a C re at iv e C om m on s A ttr ib ut io nN on C om m er ci al\n3 .0\nU np\nor te\nd L\nic en\nce .\nphotoacoustic contrast agent for stem cells labelling and tracking.20\nHowever, these nano-drug delivery systems based on bare PB NPs showed the short systemic circulation time, which extremely limited the drug accumulation at tumor sites.21 Meanwhile, the weak evading ability from macrophage uptake and strong blood clearance preference also reduced the therapy efficiency. In order to overcome these barriers, constructing a bio-mimetic nano-drug delivery system by adopting natural cell membranes become a new choice for improving drug accumulation at tumor region, extending half-life circulation and reducing immunogenicity, which has been primarily conrmed by the series study.22–25 Undoubtedly, the coating of the membrane system on nanoparticles improved the therapy efficiency through enhanced permeability and retention (EPR) effect in some extent, the passive accumulation of chemical drugs without actively aiming towards the solid tumors oen resulted in high cost and unsatised tumor therapy outcomes.26–28 Meanwhile, these drug delivery systems with a fast release and wild distribution still caused considerable adverse effects to normal tissues.\nFolate receptor is a glycosyl phosphatidyl inositol (GRI)linked membrane protein, which oen highly expressed in several kinds of solid tumor including cervical carcinoma, hepatocarcinoma and human oral epidermoid carcinoma cells, etc.29,30 By using the high affinity to folate receptors, it has been widely used on drug delivery system for tumor targeting therapy, and the result demonstrated that the tumor-specic targeting nanocarriers obtained high efficient tumor therapy by improving cell uptake and targeted drug release.31,32 In this study, by combining the characteristics of PB NPs with an ultralarge surface area and hollow cavities, FA with specic targeting capacity and red cell membrane with immune stealthy ability, we constructed a smart and dual-modal nano-drug delivery system for combinational therapy of cervical carcinoma aer evaluating its biocompatibility, loading capacity, release performance and cell-killing ability in vivo. The protocol proposed in Scheme 1 showed the preparation of SCPB@DOX@EM@FA NPs and its application in vitro and in vivo."
    }, {
      "heading" : "Experimental",
      "text" : "Preparation of spheric & cubic hollow mesopores Prussian blue (SCPB NPs)\nThe method of preparing cubic HMPB NPs was prepared as previously reported with modication.5 Briey, K3[Fe$(CN)6]$ 3H2O (264 mg) and PVP (3 g) were dissolved in the HCl solution (0.01 M) and stirred for 1 h. Then, the yellowmixture was heated in an oil bath at 80 C for 20 h. Aer through centrifugation (12 000 rpm), washing with water and vacuum drying, cubic PB NPs were acquired. Then, the obtained PB NPs (20 mg) and PVP (100 mg) were mixed in the HCl solution and placed in a reaction vessel at 80 C for 6 h. The cubic HMPB NPs were collected aer washing with water. The spheric hollow mesopores Prussian blue nanoparticles was obtained by change the amount of K3[Fe$(CN)6]$3H2O to 66 mg under similar conditions. Then,\n27912 | RSC Adv., 2019, 9, 27911–27926\nthe mixed of cubic and spheric HMPB NPs with different mass ratios were stirred (800 rpm) for 4 h so as to obtain the cubic and spheric hollow mesopores Prussian blue nanoparticles."
    }, {
      "heading" : "Preparation of erythrocyte membrane",
      "text" : "Whole blood taken from mice or human was washed with PBS (pH 7.4) and centrifuged at 3000 rpm for 5 min to remove the plasma. Aer hemolysis in 0.25 PBS (pH 7.4) for 1 h at 4 C, the hemolyzed blood is centrifuged at 12 000 rpm for 10 min and washed with PBS (pH 7.4) until the supernatant became colorless. The re-dispersed EM in PBS (pH 7.4) was sonicated at 4 C for 30 min. The broken EM was sequentially passed through 0.45 mm and 0.2 mm lter to get EM with uniform particle size. The content of membrane protein in EM was measured using the BCA protein assay kit."
    }, {
      "heading" : "Preparation of SCPB@DOX NPs and SCPB@DOX@EM NPs",
      "text" : "The mixture containing 1 mL of SCPB NPs (1 mg mL 1) and 1 mL of DOX (1 mg mL 1) was stirred at 800 rpm for 12 h. Subsequently, the unloaded DOX was removed through dialyzing using dialysis bag (MWCO of 3 kDa) for 12 h to obtain SCPB@DOX NPs solution. SCPB@DOX@EM NPs solution was prepared by adding EM (1 mg mL 1, 1 mL) into the SCPB@DOX NPs aqueous and stirred at 800 rpm at 4 C overnight."
    }, {
      "heading" : "Preparation of SCPB@DOX@EM@FA NPs",
      "text" : "100 mg of EDC and 50 mg of NHS were sequentially added into SCPB@DOX@EM NPs (0.5 mg mL 1, 2 mL) solution and stirred at 4 C for 4 h. Aer that, 10 mg DSPE-PEG-NH2 was added into the mixed solution and stirred at 4 C for 6 h. Then, 1.5 mg of FA was added and stirred at 4 C overnight. The obtained solution was dialyzed using a dialysis bag (MWCO of 10 kDa).\nDrug loading and release in vitro\nVarious concentrations of DOX (125, 250, 500, 1000, 2000, 3000 mg mL 1, 500 mL) were loaded into SCPB NPs (1 mg mL 1, 1 mL) to synthesize SCPB@DOX NPs. The concentration of DOX in the dialysis bag was measured on the microplate reader. The DOX loading efficiency (LC) and encapsulation efficiency (EC) were calculated according to the following eqn (1) and (2).\nLCð%Þ ¼ Mt Mu Mp 100% (1)\nECð%Þ ¼ Mt Mu Mt 100% (2)\nwhere Mt, Mu, and Mp are the mass of the added DOX, the unencapsulated DOX, and the mass of SCPB NPs, respectively.\nTo investigate the release of DOX at different pH conditions, samples were divided into 4 groups including (1) SCPB@DOX NPs (pH 5.0), (2) SCPB@DOX NPs (pH 7.4), (3) SCPB@DOX@EM@FA NPs (pH 5.0), (4) SCPB@DOX@EM@FA NPs, PBS buffer (10 mM, pH 7.4) and acetate buffer (10 mM, pH 5.0). As for the DOX release efficiency, 1 mL of SCPB@DOX NPs (2 mg mL 1) solution sealed in the dialysis bag were immersed in\nThis journal is © The Royal Society of Chemistry 2019\nScheme 1 Illustration of the preparation and anti-tumor application of drug loaded SCPB@DOX@EM@FA NPs.\nO pe\nn A\ncc es\ns A\nrt ic\nle . P\nub lis\nhe d\non 0\n4 Se\npt em\nbe r\n20 19\n. D ow\nnl oa\nde d\non 9\n/1 6/\n20 19\n8 :5\n3: 01\nA M . T hi s ar tic le is li ce ns ed u nd er a C re at iv e C om m on s A ttr ib ut io nN on C om m er ci al\n3 .0\nU np\nor te\nd L\nic en\nce .\n20 mL of PBS buffer (pH 7.4) or 20 mL acetate buffer (pH 5.0). The same treatment was performed for SCPB@DOX@EM@FA NPs (2 mg mL 1) solution. 2 mL of dialysate was taken out at intervals of 12 h and the same volume of the fresh PBS solution or acetate solution was replenished. The amount of released DOX was monitored using a microplate reader. The nearinfrared light-triggered release of DOX was studied by treating 2 mL of SCPB@DOX@EM@FA NPs solution with 4 cycles of the laser on/off under different pH values (pH 5.0 or 7.4) using an 808 nm NIR laser (0.8 W cm 2, 10 min for laser on, 20 min for laser off)."
    }, {
      "heading" : "Photothermal effect of SCPB@DOX@EM@FA NPs:",
      "text" : "EP tubes containing 0.5 mL of PBS (pH 7.4), SCPB@DOX NPs (0.2 mg mL 1), SCPB@DOX@EM NPs (0.2 mg mL 1) or SCPB@DOX@EM@FA NPs (0.2 mg mL 1) were irradiated with the near-infrared light (808 nm, 0.8 W cm 2) for 5 min and the temperature was recorded using a thermal infrared imaging camera every 1 min. To investigate the photostability of SCPB@DOX@EM@FA NPs, 1 mL SCPB@EM@FA NPs (0.2 mg mL 1) solution or ICG (0.2 mg mL 1) aqueous solution was\nThis journal is © The Royal Society of Chemistry 2019\nirradiated with 808 nm laser for 5 min and then cooled down to the room temperature in 5 min. Aer repeating for 6 cycles, the UV-Vis absorbance spectra of the two solutions before and aer the irradiation were recorded."
    }, {
      "heading" : "Intracellular DOX release",
      "text" : "HeLa, MDA-MB-231, NIH-3T3, SMMC-7721 and BGC-823 cells were cultured in DMEM medium containing 10% Fetal Bovine Serum (FBS) and 1% streptomycin/penicillin, respectively. Cells were cultured at 37 C in a humidied atmosphere with 5% CO2. Cell samples divided into 5 groups were subjected with different treatment: (1) DOX, (2) SCPB@DOX NPs, (3) SCPB@DOX@EM NPs, (4) SCPB@DOX@EM@FA NPs, (5) SCPB@DOX@EM@FA NPs, near-infrared (808 nm, 0.8 W cm 2) for 5 min. HeLa cells were seeded into confocal dishes at a density of 5 104 cells per dish and incubated for 24 h. Then, the medium was replaced by fresh medium containing DOX, SCPB@DOX NPs, SCPB@DOX@EM NPs, and SCPB@DOX@EM@FA NPs and incubated at 37 C for 3 h. The concentration of DOX and SCPB were 10 mg mL 1 and 20 mg mL 1, respectively. Aer that, the cells of the group (5) was irradiated under\nRSC Adv., 2019, 9, 27911–27926 | 27913\nO pe\nn A\ncc es\ns A\nrt ic\nle . P\nub lis\nhe d\non 0\n4 Se\npt em\nbe r\n20 19\n. D ow\nnl oa\nde d\non 9\n/1 6/\n20 19\n8 :5\n3: 01\nA M . T hi s ar tic le is li ce ns ed u nd er a C re at iv e C om m on s A ttr ib ut io nN on C om m er ci al\n3 .0\nU np\nor te\nd L\nic en\nce .\nNIR for 5 min and incubated at 37 C for 1 h. Meanwhile, the cell nuclei were stained with Hoechst 33342 for 30 min. The cells were observed under a laser scanning confocal microscope."
    }, {
      "heading" : "Hemolysis assay",
      "text" : "A hemolysis assay was performed using fresh human blood samples provided by the People's Hospital of Hunan province. The erythrocytes were collected via centrifugation at 3000 rpm for 5 min at 4 C, and washed 5 times with PBS solution to get pure erythrocytes. Aerward, 50 mL of 4% erythrocytes (v/v) was mixed with 950 mL of SCPB@DOX NPs, SCPB@DOX@EMNPs or SCPB@DOX@EM@FA NPs solution (dissolved in PBS with pH 7.4) at various concentrations (25, 50, 100 and 200 mg mL 1), and the resulting mixture was incubated at 37 C for 4 h. The positive control used erythrocytes mixed with pure water as 100% hemolysis. The samples were centrifuged at 3000 rpm for 5 min at 4 C, and the absorbance of the supernatant at 540 nm was measured using a UV-Vis spectrophotometer. The percentage of hemolysis was calculated using the formula (3).\nHemolysis (%) ¼ (I/I0) 100% (3)\nwherein I represent the absorbance of the supernatant aer addition of erythrocytes suspension by SCPB@DOX NPs, SCPB@DOX@EM NPs or SCPB@DOX@EM@FA NPs, and I0 represents the absorbance of erythrocytes aer complete hemolysis in pure water. All hemolysis experiments were performed in triplicate."
    }, {
      "heading" : "MTT assay",
      "text" : "The cytotoxicity of SCPB@EM@FA NPs to HeLa, MDA-MB-231, NIH-3T3, SMMC-7721, and BGC-823 cells were evaluated. Briey, cells seeded into 96-well plate were cultured for 24 h. Aer washing with PBS, cells were exposed to the medium containing SCPB@EM@FA NPs (SCPB concentrations of 25, 50, 100 and 200 mg mL 1) for 24 h. Aer washing with PBS for 3 times, 100 mL of MTT solution (0.5 mgmL 1) was added and the cells were cultured for another 4 h, the supernatant was carefully removed and 100 mL of DMSO was added to each well. Cell viabilities were calculated according to the formula (4).\nCell viability ¼ OD490 nm=sample OD490 nm=control 100% (4)\nAer culturing for 24 h, the medium of HeLa cells were replaced by fresh medium containing DOX (1 mg mL 1), SCPB NP (20 mg mL 1), SCPB@DOX NPs (SCPB concentration of 20 mg mL 1, DOX concentration of 1 mg mL 1), SCPB@DOX@EM NPs (SCPB concentration of 20 mg mL 1, DOX concentration of 1 mg mL 1), SCPB@DOX@EM@FA NPs (SCPB concentration of 20 mg mL 1, DOX concentration of 1 mgmL 1) or PBS (10mM, pH 7.4), respectively. 4 h later, the cells were irradiated with or without an 808 nm NIR laser (0.8 W cm 2) for 5 min. The cells were further incubated for 20 h before the cell viability was assayed.\n27914 | RSC Adv., 2019, 9, 27911–27926"
    }, {
      "heading" : "Immune escape experiment",
      "text" : "All animal experiments were conducted in the Laboratory Animal Center of Xiangya School of Medicine under the guidance of the center. 5 female BALB/c mice (5 week old) were injected intraperitoneally with 1 mL of DMEM for 3 consecutive days. On the 4th day, mice were intraperitoneally injected with 15 mL of DMEM. The abdomen of euthanized mice was licked for 20 min. Then, the intra-abdominal tissue uid was aspirated and centrifuged at 1000 rpm for 5 min. Obtained cells were cultured for 24 h aer washing with the medium; then, the adherent macrophages were treated with lipopolysaccharide (LPS, the nal concentration of 1 mg mL 1), SCPB@DOX NPs (0– 20 mg mL 1) or SCPB@DOX@EM@FA NPs (0–20 mg mL 1) for another 12 h to collect the supernatant. The level of TNF-a was measured using an Elisa kit, and the adhered cells were imaged under a confocal microscope.\nIn vitro specic targeting\nNIH-3T3, SMMC-7721, BGC-823, MDA-MB-231, and HeLa cells were seeded at a density of 1 105 cells per dish and incubated for 12 h. To explore the targeting effect of FA modication, cells were pretreated with 10 mM free FA for 30 min. Then, the medium was replaced with fresh medium containing SCPB@DOX@EM@FA NPs (DOX concentration of 1 mg mL 1). The cell nuclei were stained with Hoechst 33342 aer culturing for 4 h. All samples were imaged under a laser scanning confocal microscope."
    }, {
      "heading" : "Apoptosis assay",
      "text" : "Aer culturing for 24 h, HeLa cells were incubated with different materials containing PBS, SCPB NPs, DOX, SCPB@DOX NPs, SCPB@DOX@EM NPs or SCPB@DOX@EM@FA NPs (with DOX concentration of 0.5 mg mL 1) for 4 h, then, the cells were irradiated with or without an 808 nm NIR laser (0.8 W cm 2) for 5 min and were further incubated for 20 h. The harvested cells were co-stained with Annexin V-Alexa Fluor 488 and PI detection kit for ow cytometry analysis."
    }, {
      "heading" : "Calcein-AM/PI staining assays",
      "text" : "5 105 HeLa cells seeded into the 12-well plate were cultured for 24 h, followed by incubating with PBS, SCPB NPs, DOX, SCPB@DOX NPs, SCPB@DOX@EM NPs or SCPB@DOX@EM@FA NPs (0.5 mg mL 1 DOX) for 4 h. Then, cells were irradiated with or without an 808 nm NIR laser (0.8 W cm 2) for 5 min. Aer incubating for another 20 h, cells were stained with Calcein-AM/PI and imaged under the confocal microscope."
    }, {
      "heading" : "Western blotting",
      "text" : "HeLa cells were incubated with cell culture medium containing PBS, SCPB NPs, DOX, SCPB@DOX NPs, SCPB@DOX@EM NPs or SCPB@DOX@EM@FA NPs (0.5 mg mL 1 DOX) for 4 h. Then, the cells were irradiated with or without an 808 nm NIR laser (0.8 W cm 2) for 5 min and further incubated for 20 h. The treated cells were lysed in the RIPA buffer. Aer separating with SDS-polyacrylamide gel electrophoresis (SDS-PAGE), proteins\nThis journal is © The Royal Society of Chemistry 2019\nO pe\nn A\ncc es\ns A\nrt ic\nle . P\nub lis\nhe d\non 0\n4 Se\npt em\nbe r\n20 19\n. D ow\nnl oa\nde d\non 9\n/1 6/\n20 19\n8 :5\n3: 01\nA M . T hi s ar tic le is li ce ns ed u nd er a C re at iv e C om m on s A ttr ib ut io nN on C om m er ci al\n3 .0\nU np\nor te\nd L\nic en\nce .\nwere transferred into nitrocellulose membranes. The membranes were incubated with antibodies against PARP, IKK, NF-kB, caspase-3, BAX, Bcl-2 and b-actin overnight at 4 C aer blocking with 5% skim milk, followed by incubation with HRPconjugated secondary antibodies. The bands were visualized using the BIO-RAD ChemiDoc XRS chemiluminescence system.\nIn vivo multimodal imaging\nFemale BALB/c mice (5 week old) were used under regulation approved by the Laboratory Animal Center of the Xiangya School of Medicine, Central South University (Changsha, China). All the animal experiments were performed under the guidelines approved by the Medical Laboratory Animal Management Committee of the Xiangya School of Medicine. For in vivo imaging and investigating photothermal effects, 100 mL of SCPB@ICG NPs, SCPB@ICG@EM NPs or SCPB@ICG@EM@FA NPs were injected intravenously into HeLa tumorbearing nude mice (with ICG concentration of 2.5 mg kg 1). ICG-labeling was used to avoid the interference of the uorescence of the organism itself on imaging. In vivo uorescent imaging was performed at 12, 24, 36, and 48 h post-injection using a Kodak multimode imaging system (Ex/Em ¼ 740 nm/ 820 nm). Mice (n ¼ 3) were intravenously injected with 100 mL of SCPB@DOX NPs, SCPB@DOX@EM NPs or SCPB@DOX@EM@FA NPs (2.5 mg kg 1 DOX) and then irradiated using NIR laser (5 min, 808 nm, and 0.8 W cm 2) at 24 h post-injection, respectively. A thermal infrared camera was used to monitor the local temperature change of the tumor site. For in vitro distribution, the tumor and the major organs (heart, liver, spleen, lung, and kidney) were carefully collected at 48 h postinjection and imaged using Kodak multimode imaging system. Aer intravenous administration of 100 mL SCPB@DOX@EM@FA NPs (SCPB concentration of 1 mg mL 1), the PA imaging of mice was acquired at 24 h post-injection using a commercial Endra Nexus 128 PA tomography system equipped with a tunable nanosecond pulsed laser.\nPharmacokinetics and in vivo distribution\nThe eyelid blood of tumor-bearing mice was collected at different time points (0, 1, 2, 4, 8, 12, 24, 48 h) aer vein administration with SCPB NPs, SCPB@DOX@EM@FA NPs (100 mL, SCPB dosage at 5.0 mg kg 1). Aer injection for 24 h, vital organs (heart, liver, spleen, lung, kidney) and tumors were collected and lysed in the mixture of HClO4 and HNO3 (HClO4 : HNO3 ¼ 1 : 10, v/v) for ICP-OES analysis.\nIn vivo antitumor effect and safety evaluation\nTo develop a tumor xenogra model, female BALB/c mice were subcutaneously injected with HeLa cells in the logarithmic growth phase. Aer reaching the tumor size of 100 mm3, mice were divided into 9 groups (n ¼ 3 per group): (1) PBS, (2) PBS + laser, (3) DOX, (4) SCPB@DOX NPs, (5) SCPB@DOX NPs + laser, (6) SCPB@DOX@EM NPs, (7) SCPB@DOX@EM NPs + laser, (8) SCPB@DOX@EM@FA NPs, (9) SCPB@DOX@EM@FA NPs + laser. Nano-drug (100 mL, 2.5 mg kg 1, DOX; 100 mL, 5 mg kg 1, SCPB) was injected through the tail vein once every 2 days for 8\nThis journal is © The Royal Society of Chemistry 2019\ntimes in the rst 16 days. Aer administration for 24 h, the tumor site of the mouse was irradiated with 808 nm laser (0.8 W cm 2) for 5 min. Changes in tumor length (L: mm) and width (W: mm) were measured using vernier calipers. Body weight and tumor volume were recorded every other day. The tumor volume (V) was calculated by the eqn (5):\nV ¼ L W2/2 (5)\nAer 18 days, vital organs (heart, liver, spleen, lung, and kidney), as well as tumors, were collected from euthanized mice and xed with formalin. The paraffin sections of tumor and vital organs were performed for H&E staining and TUNEL apoptosis assays. The tumor growth inhibition (TGI) rate was calculated according to eqn (6):\nTGIð%Þ ¼ Vc Vt Vc 100% (6)\nwhere Vc represents the tumor volume of the control group, and Vt represents the tumor volume aer the treatments. For biochemistry analysis blood plasma was obtained from mice blood aer centrifugation."
    }, {
      "heading" : "Statistical analysis",
      "text" : "SPSS version 22 was used for statistical analysis. All data were obtained in triplicate and presented as mean standard deviation. One-way ANOVA was used followed by Tukey's post-test for all data analysis and P value of *P < 0.05, **P < 0.01, ***P < 0.001 was noted as statistically signicant."
    }, {
      "heading" : "Results and discussion",
      "text" : "Characterization and photothermal properties of SCPB NPs\nFirst, various characterizing methods including XRD patterns, N2 adsorption–desorption isotherms, and the pore size distribution prole, FTIR spectra, UV-Vis spectra, were used to demonstrate the successful synthesis of the spheric, spheric & cubic and cubic HMPB NPs, which was indicated as Fig. S1.† Meanwhile, SEM images conrmed the typical size of 130 nm and regular shape of HMPB NPs (Fig. 1A and B). Considering the light absorption property of PB NPs was reected by the parameters of molar extinction coefficient (3) and the photothermal conversion efficiency (h),5,18 we then used eqn (S2) and (S7)†33,34 to determine their values and found that the cubic HMPB NPs possessing a larger nanoparticle volume in the same case showed a larger 3 value comparing with the spheric HMPB NPs (1.17 1013 vs. 2.8 1013), while the h of the spheric HMPB NPs is larger than the cubic HMPB NPs (47.75% vs. 37.05%), (see the ESI† part 1 for the detailed calculations). As the heat energy release efficiency of NPs with near-infrared light exposure is closely related to the shape, size, etc.,35–37 we proposed a hypothesis that the mixture of spheric and cubic HMPB NPs maybe improve the photothermal conversion performance, which is highly demanding for obtaining NIR-induced cancer photothermal ablation (PTA). In order to conrm it, the temperature of the samples containing spheric and cubic HMPB NPs mixtures (ratios from 4 : 1 to 1 : 4) under laser\nRSC Adv., 2019, 9, 27911–27926 | 27915\nFig. 1 (A and B) Scanning electron microscope (SEM) images. (C) The molar extinction coefficient and photothermal conversion efficiency of spheric, spheric & cubic and cubic HMPB NPs. (D) Temperature change during 808 nm laser irradiation (0.8 W cm 2) of the spheric and cubic with different ratios for 5 min. (E) DOX loading efficiency and encapsulation efficiency of spheric, spheric & cubic and cubic HMPB NPs when the DOX concentration was 3.0 mg mL 1. (F) Controllable release of different DOX-loading NPs triggered by laser. (G) and (H) TEM of SPB NPs, CPB NPs and SCPB NPs with erythrocyte membrane modification (SCPB@EM NPs). (I) Surface charge of SCPB NPs, SCPB@DOX NPs, EM, SCPB@DOX@EMNPs, and SCPB@DOX@EM@FA NPs. (J) Size distribution and (K) UV-Vis absorption spectra of DOX, SCPB NPs, SCPB@DOXNPs, SCPB@DOX@EM NPs, and SCPB@DOX@EM@FA NPs. (L) SDS-PAGE of protein samples. Samples 1 to 4 is protein marker, sole erythrocyte membrane, SCPB@DOX@EM NPs, and SCPB@DOX@EM@FA NPs, respectively.\nO pe\nn A\ncc es\ns A\nrt ic\nle . P\nub lis\nhe d\non 0\n4 Se\npt em\nbe r\n20 19\n. D ow\nnl oa\nde d\non 9\n/1 6/\n20 19\n8 :5\n3: 01\nA M . T hi s ar tic le is li ce ns ed u nd er a C re at iv e C om m on s A ttr ib ut io nN on C om m er ci al\n3 .0\nU np\nor te\nd L\nic en\nce .\nirradiation (0.8 W cm 2 for 5 min) was investigated. The results in Fig. 1D showed that comparing to pure spheric and cubic HMPB NPs, the temperature increased in all mixture was maximum of 32.4 C when the ratio is 1 : 1. This result indicates that the co-presence of two different kinds of HMPB NPs really improved the photothermal conversion performance, which is benecial for triggering loaded drug release. As shown in Fig. 1E and F, at the condition of same loading capacity and entrapment capacity, DOX release rate of mixture is higher than any\n27916 | RSC Adv., 2019, 9, 27911–27926\npure NPs, which indicated the improved efficiency of DOX release under laser. Thus, the mixed PB NPs with improved photothermal conversion performance and drug release rate can be ideally used for combinational tumor theranostics."
    }, {
      "heading" : "Physiochemical characterization of SCPB@DOX@EM@FA NPs",
      "text" : "Then, FA-modied erythrocyte membrane was used to coat DOX-loading SCPB to improve the biocompatibility and\nThis journal is © The Royal Society of Chemistry 2019\nO pe\nn A\ncc es\ns A\nrt ic\nle . P\nub lis\nhe d\non 0\n4 Se\npt em\nbe r\n20 19\n. D ow\nnl oa\nde d\non 9\n/1 6/\n20 19\n8 :5\n3: 01\nA M . T hi s ar tic le is li ce ns ed u nd er a C re at iv e C om m on s A ttr ib ut io nN on C om m er ci al\n3 .0\nU np\nor te\nd L\nic en\nce .\ntargeting the ability of this system. The TEM image in Fig. 1G and H showed the average size of SCPB NPs of 130 nm, and a lm coating of approximately 5 nm on the surface of SCPB NPs upon the erythrocyte membrane coating. In addition, the surface zeta potential of SCPB@DOX NPs changed from 5.2 mV to 15.6 mV following membrane coating and folic acid modication (Fig. 1I). Compared with DOX-loaded SCPB NPs (mean size of 164 nm), the coating of the cell membrane and FA conjugation showed the weak increase in particle size and size distribution (171 nm and 185 nm) (Fig. 1J). Meanwhile, the UV-Vis spectra of SCPB@DOX@EM@FA NPs showed characteristic absorption peaks including 714 nm of SCPB NPs, 480 nm of DOX and 405 nm of the erythrocyte membrane, respectively (Fig. 1K). Moreover, the confocal laser scanning microscope (CLSM) image directly indicated the successful encapsulation of SCPB NPs with erythrocyte membrane (Fig. S2A†). In addition, the assay using SDS-PAGE method conrmed that nearly all of the endogenous membrane proteins were preserved on the SCPB@DOX@EM@FA NPs comparing with natural erythrocyte membrane (Fig. 1L). Furthermore, EDS analysis displayed the composition of SCPB@EMNPs with C, N, Fe and P elements, which also proved the camouage of EM on the surface of SCPB NPs (Fig. S2B†). FTIR spectroscopy (Fig. S2C†) showed the absorbance peak at 2090 cm 1, which indicated –CN– stretching in the Fe–CN–Fe bond of SCPB NPs. The absorbance peak of SCPB@EM NPs at 1680 indicated the characteristic amide I band of the erythrocyte membrane (Fig. S2C†). Comparing with pure SCPB NPs, there is no agglomeration, indicating the high stability of SCPB@DOX@EM@FA NPs. Together, these results indicate that spheric & cubic HMPB NPs are successfully synthesized and the folate-targeted modied erythrocyte membrane effectively wraps the surface of SCPB NPs. Thus, the desired nanosystem was created.\nIn vitro photothermal properties and drug release of SCPB@DOX@EM@FA NPs\nThe charge transition between Fe2+ and Fe3+ ions induced by energy change under NIR light can result in a high molar extinction coefficient and photo-thermal property of PB NPs.38 Bymeasuring the temperature change of different PB NPs under laser irradiation, it was found that the temperature of the PBS solution only increased 3.8 C aer 5 min irradiation at a power density of 0.8 W cm 2. However, the temperature of a solution containing SCPB NPs increased about 33.4 C aer with same treatment (from 30 to 63.4 C) (Fig. 2A), which clearly reected the efficient energy conversion of SCPB NPs induced by the laser irradiation.38 Moreover, the samples of SCPB@DOX NPs, SCPB@DOX@EM NPs, and SCPB@DOX@EM@FA NPs showed similar photothermal conversion efficiency comparing with SCPB NPs. These results indicate that the different modication including FA and EM negligibly affected the photothermal conversion efficiency of SCPB NPs, which is necessary for the following photothermal therapy. In addition, the photostability of SCPB@EM@FA NPs with ICG, an FDA-approved photothermal agent, was also compared. Fig. 2B indicated that the\nThis journal is © The Royal Society of Chemistry 2019\ntemperature change caused by SCPB@EM@FA NPs is more than 30 C aer exposure to 808 nm for 6 heating–cooling cycle, which is signicantly higher (30 C vs. 24 C) than that of ICG with the same treatment. These results clearly indicate its excellent photothermal stability SCPB@EM@FANPs comparing with ICG. UV-Vis absorption spectra also conrmed it as no signicant change of absorption peak was observed for SCPB@EM@FA NPs aer with strong irradiation for 30 min. In contrary, the peak of ICG almost disappeared (Fig. 2C). We then performed the drug loading assay under the different ratio of DOX/PB. As shown in Fig. 2D, the highest loading efficiency of SCPB NPs to DOX is 130.69% at the optimal ratio of DOX/PB with 3 : 1, which is comparable with previous reports.5 By combining with above result of pore-size distribution, nitrogen adsorption–desorption isotherm and UV-Vis absorption spectra, we suspected that the extremely high loading capacity can be attributed to the following factors: (1) the hollow mesoporous structure with a large cavity and numerous mesoporous (Fig. S1F and G†); (2) the electrostatic interaction between positively charged DOX and negatively charged SCPB NPs (Fig. 2C), and the strong coordination bond between the Fe(III) inherent in the SCPB NPs structure and the amino or carbonyl group of DOX.18\nAs both high temperature and acidic conditions can directly destroy the erythrocyte membrane, which is benecial for drug release,39 we rst monitored the effect of pH on the DOX release behavior in the period of 72 h and found that the maximal drug cumulative rate of SCPB@DOX@EM@FA NPs at pH 5.0 increased about 2.5-fold compared with that of sample at pH 7.4 (57.78% vs. 22.2%) (Fig. 2E). By further investigate the effect of laser irradiation on the DOX release under different pH conditions, it was found that the maximal drug cumulative rate at pH 5.0 increased to 79.70% aer with 4 cycles of the laser on/off treatment. As a contrast, same treatment only resulted in the drug release to 66.04% at the condition of pH 7.4 (Fig. 2F). From the above data, it can be concluded that the release behavior of DOX is pH and temperature-dependent. More interestingly, the release rate of DOX is remarkably increased with the help of laser irradiation, which was reected by the release curve slope change from 0.34 to 2.20. These results mean that DOX can be released with precise dosage control under the stimulation of NIR laser during the whole treatment phase, which can significantly improve the utilization of chemical drugs.\nBiocompatibility and the immune evading ability of SCPB@DOX@EM@FA NPs\nNext, the biocompatibility of these nanomaterials from different aspects was evaluated. Fig. 3A indicated that all samples could not cause hemolysis (less than 3% hemolysis rate) aer incubating with blood for 4 h. Moreover, SCPB NPs with EM coating reduced hemolysis rate to 1% even at the 200 mg mL 1. Meanwhile, these nanocomposites with the high concentration of 200 mg mL 1 did not show obvious toxicity to cultured cells in vitro, which was reected by the high cell viability (more than 85%) of NIH-3T3, SMMC-7721, HeLa, MDAMB-231 and BGC-823 (Fig. 3B). In addition, the immune-\nRSC Adv., 2019, 9, 27911–27926 | 27917\nFig. 2 (A) Infrared thermal images of (1) PBS, (2) SCPB NPs, (3) SCPB@DOX NPs, (4) SCPB@DOX@EM NPs and (5) SCPB@DOX@EM@FA NPs (with SCPB concentration at 0.2 mg mL 1) during 808 nm laser irradiation (0.8 W cm 2) for 5 min. (B) Photostability of SCPB@EM@FA NPs (with SCPB concentration at 0.2 mg mL 1) under 808 nm laser irradiation (0.8 W cm 2) using ICG as control and (C) UV-Vis spectra of ICG and SCPB@EM@FA NPs (with SCPB concentration at 0.2 mgmL 1) before and after 808 nm laser irradiation. Inset: images of SCPB@EM@FA NPs and ICG before and after 808 nm laser irradiation. (D) DOX loading efficiency and encapsulation efficiency of SCPB@DOX NPs when the DOX concentration was 0.125, 0.25, 0.5, 1.0, 2.0 and 3.0 mg mL 1, respectively. (E) DOX release from SCPB@DOX NPs and SCPB@DOX@EM@FA NPs at pH 5.0 and 7.4. (F) DOX release behavior from SCPB@DOX@EM@FA NPs with 4 laser on/off cycles. All release studies were performed in triplicate.\nO pe\nn A\ncc es\ns A\nrt ic\nle . P\nub lis\nhe d\non 0\n4 Se\npt em\nbe r\n20 19\n. D ow\nnl oa\nde d\non 9\n/1 6/\n20 19\n8 :5\n3: 01\nA M . T hi s ar tic le is li ce ns ed u nd er a C re at iv e C om m on s A ttr ib ut io nN on C om m er ci al\n3 .0\nU np\nor te\nd L\nic en\nce .\nevading assay indicated that macrophages emitted a strong red uorescence signal with a concentration-depending manner aer culturing with SCPB@DOX NPs. In contrary, the extremely\n27918 | RSC Adv., 2019, 9, 27911–27926\nweak red uorescence signal was observed in macrophages incubating with SCPB@DOX@EM@FA NPs (Fig. 3C). These results demonstrate that the camouage of EM signicantly\nThis journal is © The Royal Society of Chemistry 2019\nFig. 3 (A) Hemolysis quantification of EM incubated with SCPB@DOXNPs, SCPB@DOX@EMNPs, and SCPB@DOX@EM@FA NPs. (B) Cytotoxicity of SCPB@EM@FA NPs to different cell lines. (C) The confocal scanning microscope images of macrophages after culturing with SCPB@DOX NPs or SCPB@DOX@EM@FA NPs for 12 h, the control was without treatment (scale bar ¼ 50 mm). (D) The effect of SCPB@DOX NPs or SCPB@DOX@EM@FA NPs on the TNF-a secretion. The TNF-a levels in PBS and lipopolysaccharide (LPS)-treated macrophages were negative control (0%) and positive control (100%), respectively.\nO pe\nn A\ncc es\ns A\nrt ic\nle . P\nub lis\nhe d\non 0\n4 Se\npt em\nbe r\n20 19\n. D ow\nnl oa\nde d\non 9\n/1 6/\n20 19\n8 :5\n3: 01\nA M . T hi s ar tic le is li ce ns ed u nd er a C re at iv e C om m on s A ttr ib ut io nN on C om m er ci al\n3 .0\nU np\nor te\nd L\nic en\nce .\nimproved the immune stealthy ability of SCPB NPs from macrophages. ELISA assay also indicated that the TNF-a level in the SCPB@DOX@EM@FA NPs treatment group decreased by about 50% comparing with SCPB NPs treatment group (Fig. 3D). In summary, EM-coated SCPB NPs efficiently reduced macrophage phagocytosis and immune response, which was benecial for prolonging the blood circulation time and extending the half-life of SCPB@DOX@EM@FA NPs in vivo.\nTargeting and uptake mechanism of SCPB@DOX@EM@FA NPs\nAs a tumor marker overexpressed in more than 90% of ovarian carcinomas, folate receptor (FR) has been widely used as an efficient molecular target for tumor therapy.40 We investigated the cytotoxicity and FR expression levels of FR-positive HeLa cell lines and FR-negative SMMC-7721 and normal NIH-3T3 cell lines. As shown in Fig. 4A, no difference was observed for the cell viability of SMMC-7721 and NIH-3T3 cells incubated with or without FR blockers, whereas the cell viability of FR-positive HeLa cells decreased signicantly comparing with the FA block group. Meanwhile, the western blot also veried the high expression of FR in the HeLa cells compared with the other two cell lines. In addition, Fig. 4B indicated that red uorescence signal in HeLa cells incubating with SCPB@DOX@EM@FA NPs is stronger than that of SCPB@DOX@EMNPs. Meanwhile, excessive FA treatment\nThis journal is © The Royal Society of Chemistry 2019\nbefore adding SCPB@DOX@EM@FA NPs resulted in the signicant uorescence signal decrease of HeLa cells. These results suggest that SCPB@DOX@EM@FA NPs selectively accumulated in the HeLa cells with high FR expression.\nNanomaterials can pass through the cell membrane and enter into the lysosome, which is easily degraded by enzymes or acids and release into the cell cytoplasm. Therefore, the ability to enter into cells of nano-drug carriers directly determined the efficiency for tumor therapy.41 By investigating cell entry behavior of different nanomaterials system, we found that the cell uptake ability of SCPB@DOX NPs is more powerful than the naked DOX. Moreover, EM coating on the surface of SCPB@DOX NPs further enhanced the cellular uptake efficiency and lysosomal escape ability. Noteworthy, the amount of DOX in the nucleus of SCPB@DOX@EM@FA NPs increased sharply aer with laser irradiation, which reected the further improvement of lysosome escape of SCPB@DOX@EM@FA NPs and acceleration of drug release with the help of laser (Fig. 4C and S3†). The above results indicate that laser irradiation enhances the release of drug and the efficiency of entering the nucleus due to the excellent photothermal effect of SCPB NPs under laser irradiation.\nThe above ndings of cell uptake motivated us to explore the hindered mechanism. Aer performing the inhibition experiment using three kinds of inhibitors (b-cyclodextrin, rottlerin, and chloroquine), it was found that the presence of rottlerin, the\nRSC Adv., 2019, 9, 27911–27926 | 27919\nFig. 4 (A) Cell viability (up) and FR expression level assay (down) of NIH-3T3, SMMC-77221, and HeLa cell lines treated with SCPB@DOX@EM@FA NPs or FA + SCPB@DOX@EM@FA NPs. (B) Fluorescence images of HeLa cells after incubating with SCPB@DOX@EM NPs, SCPB@DOX@EM@FA NPs, and SCPB@DOX@EM/SCPB@DOX@EM@FANPs pretreated with excessive FA. (C) CLSM images of HeLa cells with different treatment (DOX, SCPB@DOX, SCPB@DOX@EM, SCPB@DOX@EM@FA, and SCPB@DOX@EM@FA + laser). The endosomes/lysosomes were stained with LysoTracker green (green). (D) Laser confocal scanning microscope images of internalization and subcellular localization of naked SCPB@DOX NPs and erythrocyte membrane coated SCPB@DOX NPs in the presence of three kinds of small-molecule inhibitors.\nO pe\nn A\ncc es\ns A\nrt ic\nle . P\nub lis\nhe d\non 0\n4 Se\npt em\nbe r\n20 19\n. D ow\nnl oa\nde d\non 9\n/1 6/\n20 19\n8 :5\n3: 01\nA M . T hi s ar tic le is li ce ns ed u nd er a C re at iv e C om m on s A ttr ib ut io nN on C om m er ci al\n3 .0\nU np\nor te\nd L\nic en\nce .\ninhibitor of micropinocytosis, signicantly reduced the uptake efficiency of tumor cells to the SCPB@DOX NPs, which was embodied by the red uorescence intensity reduction in the rottlerin treatment group compared with the control. Quantitative assay indicated that the uptake efficiency of naked SCPB NPs reduced about 98% at the presence of rottlerin (Fig. 4D). These ndings, which are consistent with the previous report,42 demonstrate that the anion nanomaterials like SCPB NPs enter into tumor cells mainly via micropinocytosis. Meanwhile, we found that the camouage of SCPB NPs with EM signicantly affected cell uptake manner. The signicant reduction of uptake was observed for the presence of b-cyclodextrin, which can block caveolae-mediated endocytosis. Cellular uptake efficiency to SCPB@DOX@EMNPs reduced about 80%. These results indicate that SCPB@DOX NPs enter cells through micropinocytosis by triggering actin-mediated membrane ruffling, while the SCPB@DOX@EM NPs enter into cells through caveolaemediated endocytosis. The mechanism of cell uptake difference with the two materials is investigating.\nIn vitro anti-tumor activity\nThe anti-cancer activity of SCPB@DOX@EM@FA NPs was assessed by Calcein-AM/propidium iodide staining in combination with MTT. Fig. 5A indicated that almost no apoptotic/dead cells were observed in the PBS or sole SCPB NPs treatment group without laser irradiation, indicating the favorable biocompatibility of this kind of nanocarrier. The dual treatment of SCPB@DOX with laser irradiation resulted in the increase of dead cell comparing with the free DOX treatment group. By contrast, almost all HeLa cells were killed aer with combinational treatment of SCPB@DOX@EM@FA NPs and laser irradiation. Fig. 5B also indicated that neither laser irradiation nor SCPB NPs has signicant cytotoxicity on HeLa cells. Cell death rate was about\n27920 | RSC Adv., 2019, 9, 27911–27926\n60% aer with SCPB@DOX@EM@FA NPs treatment. However, the dual treatment of SCPB@DOX@EM@FA NPs with laser irradiation resulted in more than 85% cell death, which is higher than that of free DOX treatment with or without laser irradiation (with cell viability of 50%) or sole SCPB NPs under laser irradiation (with cell viability of 80%). These results demonstrate that the combinational photothermal/chemotherapy using SCPB@DOX@EM@FA NPs produced a signicant synergistic anti-tumor efficacy. Moreover, FACS assay further veried the synergistic anti-tumor efficacy caused by dual therapy. As shown in Fig. 5C, the ratio of apoptosis to necrotic cells aer with synergistic chemotherapy/PTT was 93.6%, which was much higher than that of SCPB@DOX@EM@FA NPs (38.5%) treatment or SCPB@DOX NPs treatment with laser (37%). In addition, the rate of apoptosis and necrotic cells increased 12.5% aer with SCPB@DOX@EM@FA NPs treatment relative to SCPB@DOX@EMNPs. These results demonstrate that the tumors cells damaged more signicantly due to the targeting ability and synergistic chemotherapy/PTT. Finally, the protein levels of apoptosis-related genes were detected. As shown in Fig. 5D, the level of apoptosis-related proteins of NF-kB, IKK, PARP, and Bcl-2 was down-regulated compared with the control group. In contrary, the up-regulated expression of apoptotic protein BAX, cytochrome C and caspase-3 were found in the tumor cells treated with DOX, indicating a considerably enhanced apoptosis aer with combinational treatment (SCPB@DOX@EM@FA NPs + laser irradiation) (Fig. 5E and S4†).\nLong circulation and tumor targeting of SCPB@DOX@EM@FA NPs\nPhotoacoustic imaging (PA) was performed to visualize the distribution of SCPB@DOX@EM@FA NPs. Fig. 6A indicated that the PA signal intensity signicantly enhanced with the\nThis journal is © The Royal Society of Chemistry 2019\nFig. 5 In vitro anti-tumor activity of SCPB@DOX@EM@FANPs. (A) Live/dead cell staining (scale bar¼ 200 mm). (B) MTT assay. (C) Flow cytometry analysis of HeLa cells after treatment with PBS, SCPB NPs, DOX, SCPB@DOXNPs, SCPB@DOX@EMNPs and SCPB@DOX@EM@FA NPs subjected to 808 nm laser irradiation. The dashed curves denote the boundary of laser irradiation spots. (D) Protein level detection of IKK, NF-kB, caspase3, PARP, BAX, and Bcl-2 after different treatment. (E) Illustration of the SCPB@DOX@EM@FA NPs induced apoptosis pathway. Data are shown as mean standard deviation (SD), n ¼ 3. (P value: ***P < 0.001).\nO pe\nn A\ncc es\ns A\nrt ic\nle . P\nub lis\nhe d\non 0\n4 Se\npt em\nbe r\n20 19\n. D ow\nnl oa\nde d\non 9\n/1 6/\n20 19\n8 :5\n3: 01\nA M . T hi s ar tic le is li ce ns ed u nd er a C re at iv e C om m on s A ttr ib ut io nN on C om m er ci al\n3 .0\nU np\nor te\nd L\nic en\nce .\nconcentration increase of SCPB NPs, which showed a signicant concentration-dependent manner. Encouraged by the in vitro nding, PA imaging in vivo was assessed using the cervical\nThis journal is © The Royal Society of Chemistry 2019\ntumor xenogramodel. As shown in Fig. 6B, the PA signal at the tumor site is rather weak before injection of SCPB@DOX@EM@FA NPs. Aer 36 h post-injection, the PA signal increased\nRSC Adv., 2019, 9, 27911–27926 | 27921\nO pe\nn A\ncc es\ns A\nrt ic\nle . P\nub lis\nhe d\non 0\n4 Se\npt em\nbe r\n20 19\n. D ow\nnl oa\nde d\non 9\n/1 6/\n20 19\n8 :5\n3: 01\nA M . T hi s ar tic le is li ce ns ed u nd er a C re at iv e C om m on s A ttr ib ut io nN on C om m er ci al\n3 .0\nU np\nor te\nd L\nic en\nce .\napproximately 3-fold compared with the background signal (Fig. 6C). These ndings clearly indicate that the SCPB@DOX@EM@FA NPs could be hopefully applied as an acoustics agent for tumor diagnosis.\nAlthough the aim of multi-modal cancer therapy is to obtain an effective accumulation of NPs within the tumor region, the strong clearance of macrophages to general nano-drug extremely reduced the drug concentration of circulation in vivo, which accordingly affected the therapy efficiency. Owing to the presence of macrophage recognition signal of CD47, the EM membrane camouaged PB NPs can signicantly extend\nFig. 6 (A) PA mapping of SCPB@DOX@EM@FA NPs at different concent tumor-bearing mice pre-injection or post-injection of SCPB@DOX@EM intravenous injection of SCPB NPs or SCPB@DOX@EM@FA NPs. (E) Bio SCPB@DOX@EM@FANPs after injection for 48 h. In vivo fluorescence ima tail vein injection of SCPB@DOX NPs, SCPB@DOX@EM NPs and SCPB@ analysis (H) of main organs from cervical tumor-bearing nude mice after and SCPB@DOX@EM@FA NPs. Data are shown as mean standard deviat\n27922 | RSC Adv., 2019, 9, 27911–27926\ncirculation time in vivo by effectively avoiding the phagocytosis.43 By monitoring the blood retention of different NPs, approximately 23.21% dose per gram of blood (% ID g 1) of SCPB@EM@FA NPs in the blood circulation aer intravenous injection for 48 h were obtained, which was remarkably higher than that of naked SCPB NPs (7.08% ID g 1). Meanwhile, halftime for SCPB@EM@FA NPs in vivo increased 2.5-fold compared with that of naked SCPB NPs (8.6 h vs. 3.5 h) (Fig. 6D). These data demonstrate that EM camouage helps SCPB NPs stealthy to the host immune system.44 ICP-OES analysis also indicated the lower distribution of SCPB@DOX@EM@FA NPs\nrations. PA imaging (B) and the quantification analysis (C) of the HeLa-\n@FA NPs. (D) In vivo pharmacokinetic curves over a span of 48 h after\ndistribution of SCPB NPs, SCPB@DOX NPs, SCPB@DOX@EM NPs or\nges (F) of cervical tumor-bearing nudemice at 12, 24, 36 and 48 h after\nDOX@EM@FA NPs; ex vivo fluorescence images (G) and quantification\n48 h tail vein injection of PBS, SCPB@DOX NPs, SCPB@DOX@EM NPs,\nion (SD), n ¼ 6. (P value: ***P < 0.001).\nThis journal is © The Royal Society of Chemistry 2019\nO pe\nn A\ncc es\ns A\nrt ic\nle . P\nub lis\nhe d\non 0\n4 Se\npt em\nbe r\n20 19\n. D ow\nnl oa\nde d\non 9\n/1 6/\n20 19\n8 :5\n3: 01\nA M . T hi s ar tic le is li ce ns ed u nd er a C re at iv e C om m on s A ttr ib ut io nN on C om m er ci al\n3 .0\nU np\nor te\nd L\nic en\nce .\nin the heart, liver, spleen, lung, and kidney comparing with bare SCPB NPs, which suggested the capability of EM to reduce the uptake of the reticuloendothelial system of these organs. In the contrary, a higher amount of SCPB@DOX@EM@FA NPs accumulation was observed in the tumor compared with that of SCPB@DOX NPs and other groups (Fig. 6E). These results indicate that the EM coating and FA modied nanomaterials enhanced the accumulation in the tumor, which can accordingly reduce the side effects of chemotherapy drugs to normal tissues.\nTo more precisely monitor the tumor-targeting ability and distribution of nanomaterials, whole-body live imaging was performed at the course of 48 h. Fig. 6F showed that the uorescence signal in three treatment group wasmainly observed at 12 h post-injection. However, compared to SCBP@DOX NPs treatment, uorescence signals are concentrated at the tumor site by SCPB@DOX@EM@FA NPs rather than being randomly distributed in various tissues. In addition, by observing the uorescence signal distribution in the tumor-bearing mice, it was found that the strong uorescence signal appeared in the tumor aer administration with SCPB@DOX@EM@FA NPs for 48 h (Fig. 6G). It can be clearly seen from the quantitative analysis of uorescence in Fig. 6H, the intensity of the uorescence signal in the tumor region of SCPB@DOX@EM@FA NPs group was at least 2.5-fold higher than that of SCPB@DOX@EM NPs group. This result demonstrates that the specic interaction between FA and FA receptor of HeLa cells accelerated the accumulation of SCPB@DOX@EM@FA NPs at the tumor region.\nTumor growth inhibition mediated by SCPB@DOX@EM@FA NPs in vivo\nIn vivo thermal imaging was investigated to ensure that the desired temperature change was achieved at the tumor site of the mice 24 h aer intravenous injection of SCPB@DOX@EM@FA NPs. Fig. 7B showed no signicant temperature increase of tumor site was observed in PBS treatment group aer with 5 min of laser irradiation, while the temperature of the tumor site with post-injection of SCPB@DOX NPs and SCPB@DOX@EM@FA NPs increased 10.0 C and 26.0 C, respectively under same conditions. These results clearly indicated that only the existence of PB NPs could directly cause temperature increase at tumor region. Meanwhile, FA modication on the PB NPs increased the local concentration of SCPB@DOX@EM@FA NPs comparing with SCPB at the tumor site, which provides the possibility for efficient thermal therapy. By comparing with the previous study,5,10 compared with 808 nm laser irradiation group, the SCPB@DOX@EM@FA NPs (23.0 C) caused temperature change is higher than PEG and folic acid co-modied (15.9 C) or simple erythrocyte membrane-encapsulated PB NPs (19.5 C). The reason for this advantage is not only because of the targeted camouage effect of folic acidmodication and lm encapsulation but also due to the excellent photothermal properties brought by the mixed shape PB NPs.\nThis journal is © The Royal Society of Chemistry 2019\nThen, the in vivo synergistic photothermal-/chemotherapy of SCPB@DOX@EM@FA NPs were studied using cervical tumor-bearing BALB/c mice model (Fig. 7A). As shown in Fig. 7C, no signicant difference in body weight among all groups were observed over a span of 18 days aer repeated injection of NPs, indicating that these NPs (SCPB@DOX) camouaged with EM membrane have no overall side effects on the mice. In addition, the tumor growth inhibition rate (TGI) of the laser irradiation group and the DOX group was 3.5% and 53.1%, respectively. However, the combination of laser irradiation with SCPB@DOX@EM NPs showed a signicant TGI rate of 88.2%. Despite having such a signicant therapeutic effect, the tumor still has a certain risk of recurrence. Fortunately, when SCPB@DOX@EM@FA NPs was combined with laser irradiation, the TGI rate increased to 99.6% which provided a possibility to completely eradicate the tumor (Fig. 7D). The digital photograph in Fig. 7E also shows that the tumor size aer synergistic treatment is smaller than the other groups. Furthermore, the result of H&E and TUNEL-staining demonstrated that the structure of tumor tissue was broken and a large number of tumor cells in the tissue were apoptotic aer treatment with SCPB@DOX@EM@FA NPs and laser irradiation, compared with other groups (Fig. 7E). The strong anti-tumor ability of SCPB@DOX@EM@FA NPs with the help of laser irradiation indicated an effective accumulation of PB NPs and controllable release of DOX at tumor site due to the long blood circulation time, EPR effect and receptor-mediated endocytosis of tumor cells.\nToxicity of SCPB@DOX@EM@FA NPs in vivo\nAs blood-type mismatch occasionally leads to transfusion reaction and even death.44 The potential toxicity of this kind of EM-camouaged NPs should be carefully considered in vivo.45 In this study, the blood of the same mice strain was used for preparing EM, as recommended previously.46 By systematically investigating the toxicity of this kind of NPs, it was found that no obvious hepatic toxicity was caused by SCPB&DOX@EM@FA NPs, as reected from normal values of liver function markers, including alanine transaminase (ALT), alkaline phosphatase (ALP) and aspartate aminotransferase (AST) (Fig. S5A†). However, the level of creatinine (CREA) in the blood of DOX and SCPB@DOX NPs treatment groups increased, accompanied by the decrease of white blood cells (WBC) and granulocytes (GRAN) (Fig. S5B† and Table 1), indicating the renal impairment and bonemarrow suppression was caused by the DOX and SCPB@DOX NPs. However, the camouage of the erythrocyte membrane on the PB NPs signicantly reduced the toxicity of DOX to the kidney, which was reected by these normal bioparameters of other groups. In addition, no noticeable signal of organ damage was observed in the H&E stained sections (Fig. S5C†), which further indicated the biological safety of this nano-system. As uctuation in the body weight is a direct indicator for the toxicity evaluation of nanomaterials in vivo, the bodyweight of mice with different treatment was measured. As we expected that no signicant change was observed for these\nRSC Adv., 2019, 9, 27911–27926 | 27923\nFig. 7 Synergetic therapy of HeLa tumor-bearing mice with SCPB@DOX@EM@FA NPs. (A) Time schedule of treatments and experiments. (B) Infrared thermography of HeLa-bearing mice that were tail vein injected with PBS, SCPB@DOX NPs, SCPB@DOX@EM NPs, and SCPB@DOX@EM@FA NPs. (C) Relative body weight and (D) relative tumor volume of cervical tumor-bearing mice with different treatment. (E) Representative photographs of cervical tumor-bearing mice and tumors for each tested group (with NIR laser: 808 nm, 0.8 W cm 2). H&E staining and TUNEL assay of the tumor tissues after different treatment (scale bar¼ 100 mm). *P < 0.1, **P < 0.01, ***P < 0.001. All data represent means SD (n ¼ 3).\nO pe\nn A\ncc es\ns A\nrt ic\nle . P\nub lis\nhe d\non 0\n4 Se\npt em\nbe r\n20 19\n. D ow\nnl oa\nde d\non 9\n/1 6/\n20 19\n8 :5\n3: 01\nA M . T hi s ar tic le is li ce ns ed u nd er a C re at iv e C om m on s A ttr ib ut io nN on C om m er ci al\n3 .0\nU np\nor te\nd L\nic en\nce .\ninvestigated groups. Although the above ndings indicate the good biocompatibility and bio-safety of EM-coated PB, considering the difference between mice and human, the potential\n27924 | RSC Adv., 2019, 9, 27911–27926\nshort- and long-term toxicity of these materials on different models should be deeply explored before using it for clinic therapy.\nThis journal is © The Royal Society of Chemistry 2019\nO pe\nn A\ncc es\ns A\nrt ic\nle . P\nub lis\nhe d\non 0\n4 Se\npt em\nbe r\n20 19\n. D ow\nnl oa\nde d\non 9\n/1 6/\n20 19\n8 :5\n3: 01\nA M . T hi s ar tic le is li ce ns ed u nd er a C re at iv e C om m on s A ttr ib ut io nN on C om m er ci al\n3 .0\nU np\nor te\nd L\nic en\nce ."
    }, {
      "heading" : "Conclusions",
      "text" : "Herein, we have demonstrated the strategy of combining photothermal effect enhanced HMPB NPs with EM camouage and FA modication as a precise, controllable nano-drug delivery system, resulting in a controllable release and sustained accumulation of DOX. Moreover, with enhanced photothermal therapy capability of PB NPs mixture, the prepared delivery system also showed the high drug loading capacity due to the high surface area and the huge pore volumes. With the help of laser irradiation, this drug carrier was used to realize fast and precisely controllable release of the chemical drug, which is highly desirable and benecial for the patients under the different stage of cancer. According to our point, the signicant loading and desirable release performance of PB-based drug delivery system makes it an ideal alternative for loading liposoluble chemical drugs. Given the ultrahigh bio-safety, low price and high combinational therapy efficiency, the proposed strategy will produce great signicance for personalized therapy of various tumors by combining a membrane system with other drugs."
    }, {
      "heading" : "Conflicts of interest",
      "text" : "The authors declare that they have no conict of interest."
    }, {
      "heading" : "Acknowledgements",
      "text" : "This work was partially supported by the Natural Science Foundation of China (81673579 and 81874369), Hunan Province Universities 2011 Collaborative Innovation Center of Protection and Utilization of Hu-Xiang Chinese Medicine Resources and the National Standardization Project of Traditional Chinese Medicine (Grant ZYBZH-Y- HUN-23)."
    } ],
    "references" : [ {
      "title" : "Local triplecombination therapy results in tumour regression and prevents recurrence in a colon cancer",
      "author" : [ "J. Conde", "N. Oliva", "Y. Zhang", "N. Artzi" ],
      "venue" : "model, Nat. Mater.,",
      "citeRegEx" : "Conde et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Conde et al\\.",
      "year" : 2016
    }, {
      "title" : "Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modied core– shell nanoparticles",
      "author" : [ "Q. Feng", "M.-Z. Yu", "J.-C. Wang", "W.-J. Hou", "L.-Y. Gao", "X.-F. Ma" ],
      "venue" : "Biomaterials,",
      "citeRegEx" : "Feng et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Feng et al\\.",
      "year" : 2014
    }, {
      "title" : "Combination therapy: opportunities and challenges for polymer–drug conjugates as anticancer nanomedicines, Adv",
      "author" : [ "F. Greco", "M.J. Vicent" ],
      "venue" : "Drug Delivery Rev.,",
      "citeRegEx" : "Greco and Vicent,? \\Q2009\\E",
      "shortCiteRegEx" : "Greco and Vicent",
      "year" : 2009
    }, {
      "title" : "Cell Membrane Camouaged Hollow Prussian Blue Nanoparticles for Synergistic Photothermal-/Chemotherapy of Cancer, Adv",
      "author" : [ "W. Chen", "K. Zeng", "H. Liu", "J. Ouyang", "L. Wang", "Y. Liu" ],
      "venue" : "Funct. Mater., 2017,",
      "citeRegEx" : "Chen et al\\.,? \\Q2019\\E",
      "shortCiteRegEx" : "Chen et al\\.",
      "year" : 2019
    }, {
      "title" : "A Hollow-Structured CuS@ Cu2S@ Au Nanohybrid: Synergistically Enhanced Photothermal Efficiency and Photoswitchable Targeting Effect for Cancer Theranostics",
      "author" : [ "X. Deng", "K. Li", "X. Cai", "B. Liu", "Y. Wei", "K. Deng" ],
      "venue" : "Adv. Mater.,",
      "citeRegEx" : "Deng et al\\.,? \\Q2017\\E",
      "shortCiteRegEx" : "Deng et al\\.",
      "year" : 2017
    }, {
      "title" : "Smart human serum albumin-indocyanine green nanoparticles generated by programmed assembly for dualmodal imaging-guided cancer synergistic phototherapy",
      "author" : [ "Z. Sheng", "D. Hu", "M. Zheng", "P. Zhao", "H. Liu", "D. Gao" ],
      "venue" : "ACS Nano,",
      "citeRegEx" : "Sheng et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Sheng et al\\.",
      "year" : 2014
    }, {
      "title" : "Degradation kinetics of indocyanine green in aqueous solution",
      "author" : [ "V. Saxena", "M. Sadoqi", "J. Shao" ],
      "venue" : "J. Pharm. Sci.,",
      "citeRegEx" : "Saxena et al\\.,? \\Q2003\\E",
      "shortCiteRegEx" : "Saxena et al\\.",
      "year" : 2003
    }, {
      "title" : "Hyaluronic acid conjugated magnetic Prussian blue@ quantum dot nanoparticles for cancer",
      "author" : [ "Y. Yang", "L. Jing", "X. Li", "L. Lin", "X. Yue", "Z. Dai" ],
      "venue" : "theranostics, Theranostics,",
      "citeRegEx" : "Yang et al\\.,? \\Q2017\\E",
      "shortCiteRegEx" : "Yang et al\\.",
      "year" : 2017
    }, {
      "title" : "Multimodal imaging guided photothermal therapy using functionalized graphene nanosheets anchored with magnetic nanoparticles",
      "author" : [ "K. Yang", "L. Hu", "X. Ma", "S. Ye", "L. Cheng", "X. Shi" ],
      "venue" : "Adv. Mater.,",
      "citeRegEx" : "Yang et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Yang et al\\.",
      "year" : 2012
    }, {
      "title" : "Gold-nanoshelled microcapsules: a theranostic agent for ultrasound contrast imaging and photothermal therapy, Angew",
      "author" : [ "H. Ke", "J. Wang", "Z. Dai", "Y. Jin", "E. Qu", "Z. Xing" ],
      "venue" : null,
      "citeRegEx" : "Ke et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Ke et al\\.",
      "year" : 2011
    }, {
      "title" : "Synergistic cancer therapeutic effects of locally delivered drug and heat using multifunctional nanoparticles",
      "author" : [ "S.M. Lee", "H. Park", "K.H. Yoo" ],
      "venue" : "Adv. Mater.,",
      "citeRegEx" : "Lee et al\\.,? \\Q2010\\E",
      "shortCiteRegEx" : "Lee et al\\.",
      "year" : 2010
    }, {
      "title" : "PEGylated mBPEI-rGO nanocomposites facilitate hepotocarcinoma treatment combining photothermal therapy and chemotherapy",
      "author" : [ "C. Tong", "X. Zhang", "J. Fan", "B. Li", "B. Liu", "M. Daniyal" ],
      "venue" : null,
      "citeRegEx" : "Tong et al\\.,? \\Q2018\\E",
      "shortCiteRegEx" : "Tong et al\\.",
      "year" : 2018
    }, {
      "title" : "Prussian blue nanoparticles operate as a contrast agent for enhanced photoacoustic imaging",
      "author" : [ "X. Liang", "Z. Deng", "L. Jing", "X. Li", "Z. Dai", "C. Li" ],
      "venue" : "Chem. Commun.,",
      "citeRegEx" : "Liang et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Liang et al\\.",
      "year" : 2013
    }, {
      "title" : "PEGylated Prussian blue nanocubes as a theranostic agent for simultaneous cancer imaging and photothermal therapy, Biomaterials",
      "author" : [ "L. Cheng", "H. Gong", "W. Zhu", "J. Liu", "X. Wang", "G. Liu" ],
      "venue" : null,
      "citeRegEx" : "Cheng et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Cheng et al\\.",
      "year" : 2014
    }, {
      "title" : "A Prussian Blue-Based Core–Shell Hollow-Structured Mesoporous Nanoparticle as a Smart Theranostic Agent with Ultrahigh pH-Responsive Longitudinal Relaxivity",
      "author" : [ "X. Cai", "W. Gao", "M. Ma", "M. Wu", "L. Zhang", "Y. Zheng" ],
      "venue" : "Adv. Mater.,",
      "citeRegEx" : "Cai et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Cai et al\\.",
      "year" : 2015
    }, {
      "title" : "Carbon dots/Prussian blue satellite/core nanocomposites for RSC Adv",
      "author" : [ "X. Peng", "R. Wang", "T. Wang", "W. Yang", "H. Wang", "W. Gu" ],
      "venue" : null,
      "citeRegEx" : "Peng et al\\.,? \\Q2019\\E",
      "shortCiteRegEx" : "Peng et al\\.",
      "year" : 2019
    }, {
      "title" : "Safe and immunocompatible nanocarriers cloaked in RBC membranes for drug delivery to treat solid tumors",
      "author" : [ "B.T. Luk", "R.H. Fang", "C.-M.J. Hu", "J.A. Copp", "S. Thamphiwatana", "D. Dehaini" ],
      "venue" : "Theranostics, 2016,",
      "citeRegEx" : "Luk et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Luk et al\\.",
      "year" : 2016
    }, {
      "title" : "Nanoparticle-detained toxins for safe and effective vaccination",
      "author" : [ "C.-M.J. Hu", "R.H. Fang", "B.T. Luk", "L. Zhang" ],
      "venue" : "Nat. Nanotechnol.,",
      "citeRegEx" : "Hu et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Hu et al\\.",
      "year" : 2013
    }, {
      "title" : "Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer",
      "author" : [ "F. Pi", "D.W. Binzel", "T.J. Lee", "Z. Li", "M. Sun", "P. Rychahou" ],
      "venue" : "regression, Nat. Nanotechnol.,",
      "citeRegEx" : "Pi et al\\.,? \\Q2018\\E",
      "shortCiteRegEx" : "Pi et al\\.",
      "year" : 2018
    }, {
      "title" : "Mitochondria-Targeted Articial “Nano-RBCs” for Amplied Synergistic Cancer Phototherapy by a Single NIR Irradiation",
      "author" : [ "L. Zhang", "D. Wang", "K. Yang", "D. Sheng", "B. Tan", "Z. Wang" ],
      "venue" : "Adv. Sci., 2018,",
      "citeRegEx" : "Zhang et al\\.,? \\Q2018\\E",
      "shortCiteRegEx" : "Zhang et al\\.",
      "year" : 2018
    }, {
      "title" : "Erythrocyte-Cancer Hybrid Membrane Camouaged Hollow Copper Sulde Nanoparticles for Prolonged Circulation Life and Homotypic-Targeting Photothermal/ Chemotherapy of Melanoma",
      "author" : [ "D. Wang", "H. Dong", "M. Li", "Y. Cao", "F. Yang", "K. Zhang" ],
      "venue" : "ACS Nano, 2018,",
      "citeRegEx" : "Wang et al\\.,? \\Q2018\\E",
      "shortCiteRegEx" : "Wang et al\\.",
      "year" : 2018
    }, {
      "title" : "Cell-based drug delivery, Adv",
      "author" : [ "F. Pierigè", "S. Serani", "L. Rossi", "M. Magnani" ],
      "venue" : "Drug Delivery Rev.,",
      "citeRegEx" : "Pierigè et al\\.,? \\Q2008\\E",
      "shortCiteRegEx" : "Pierigè et al\\.",
      "year" : 2008
    }, {
      "title" : "Drug delivery by red blood cells: vascular carriers designed by mother nature, Expert Opin",
      "author" : [ "V.R. Muzykantov" ],
      "venue" : "Drug Delivery,",
      "citeRegEx" : "Muzykantov,? \\Q2010\\E",
      "shortCiteRegEx" : "Muzykantov",
      "year" : 2010
    }, {
      "title" : "Doorneweerd, Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inammatory diseases",
      "author" : [ "P.S. Low", "D.D.W.A. Henne" ],
      "venue" : "Acc. Chem. Res.,",
      "citeRegEx" : "Low and Henne,? \\Q2007\\E",
      "shortCiteRegEx" : "Low and Henne",
      "year" : 2007
    }, {
      "title" : "Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues",
      "author" : [ "S.D. Weitman", "R.H. Lark", "L.R. Coney", "D.W. Fort", "V. Frasca", "V.R. Zurawski" ],
      "venue" : "Cancer Res.,",
      "citeRegEx" : "Weitman et al\\.,? \\Q1992\\E",
      "shortCiteRegEx" : "Weitman et al\\.",
      "year" : 1992
    }, {
      "title" : "pH/Reductant DualResponsive Core-Cross-Linked Micelles via Facile in situ ATRP for Tumor-Targeted Delivery of Anticancer Drug with Enhanced Anticancer Efficiency",
      "author" : [ "K. Tian", "X. Jia", "X. Zhao", "P. Liu" ],
      "venue" : "Mol. Pharm.,",
      "citeRegEx" : "Tian et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Tian et al\\.",
      "year" : 2016
    }, {
      "title" : "Cell-specic, activatable, and theranostic prodrug for dualtargeted cancer imaging and therapy",
      "author" : [ "S. Santra", "C. Kaittanis", "O.J. Santiesteban", "J.M. Perez" ],
      "venue" : "J. Am. Chem. Soc.,",
      "citeRegEx" : "Santra et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Santra et al\\.",
      "year" : 2011
    }, {
      "title" : "Microscale heat transfer transduced by surface plasmon resonant gold nanoparticles",
      "author" : [ "D.K. Roper", "W. Ahn", "M. Hoepfner" ],
      "venue" : "J. Phys. Chem. C,",
      "citeRegEx" : "Roper et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "Roper et al\\.",
      "year" : 2007
    }, {
      "title" : "A review of surface plasmon resonance-enhanced photocatalysis",
      "author" : [ "W. Hou", "S.B. Cronin" ],
      "venue" : "Adv. Funct. Mater.,",
      "citeRegEx" : "Hou and Cronin,? \\Q2013\\E",
      "shortCiteRegEx" : "Hou and Cronin",
      "year" : 2013
    }, {
      "title" : "Human HSP70 Promoter-Based Prussian Blue Nanotheranostics for Thermo-Controlled Gene Therapy and Synergistic Photothermal Ablation",
      "author" : [ "Y. Liu", "G. Shu", "X. Li", "H. Chen", "B. Zhang", "H. Pan" ],
      "venue" : "Adv. Funct. Mater.,",
      "citeRegEx" : "Liu et al\\.,? \\Q2026\\E",
      "shortCiteRegEx" : "Liu et al\\.",
      "year" : 2026
    }, {
      "title" : "Hydrophilic Cu9S5 nanocrystals: a photothermal agent with a 25.7% heat conversion efficiency for photothermal ablation of cancer cells",
      "author" : [ "Q. Tian", "F. Jiang", "R. Zou", "Q. Liu", "Z. Chen", "M. Zhu" ],
      "venue" : null,
      "citeRegEx" : "Tian et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Tian et al\\.",
      "year" : 2011
    }, {
      "title" : "Prussian blue nanoparticles operate as a new generation of photothermal ablation agents for cancer",
      "author" : [ "G. Fu", "W. Liu", "S. Feng", "X. Yue" ],
      "venue" : "therapy, Chem. Commun.,",
      "citeRegEx" : "Fu et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Fu et al\\.",
      "year" : 2012
    }, {
      "title" : "Photosensitizer decorated red blood cells as an ultrasensitive light-responsive drug delivery system",
      "author" : [ "M. Gao", "A. Hu", "X. Sun", "C. Wang", "Z. Dong", "L. Feng" ],
      "venue" : "ACS Appl. Mater. Interfaces,",
      "citeRegEx" : "Gao et al\\.,? \\Q2017\\E",
      "shortCiteRegEx" : "Gao et al\\.",
      "year" : 2017
    }, {
      "title" : "Folic acid-conjugated graphene oxide as a transporter of chemotherapeutic drug and siRNA for reversal of cancer drug resistance",
      "author" : [ "X. Cao", "F. Feng", "Y. Wang", "X. Yang", "H. Duan", "Y. Chen" ],
      "venue" : "J. Nanopart. Res.,",
      "citeRegEx" : "Cao et al\\.,? \\Q2013\\E",
      "shortCiteRegEx" : "Cao et al\\.",
      "year" : 2013
    }, {
      "title" : "Advances in the study of organelles targeting nanocarriers",
      "author" : [ "X. Sun", "L. Wei", "H. Chen", "W. Liang" ],
      "venue" : "Acta Pharm. Sin.,",
      "citeRegEx" : "Sun et al\\.,? \\Q2009\\E",
      "shortCiteRegEx" : "Sun et al\\.",
      "year" : 2009
    }, {
      "title" : "Size, Shape, and Protein Corona Determine Cellular Uptake and Removal Mechanisms of Gold Nanoparticles",
      "author" : [ "L. Ding", "C. Yao", "X. Yin", "C. Li", "Y. Huang", "M. Wu" ],
      "venue" : "Small, 2018,",
      "citeRegEx" : "Ding et al\\.,? \\Q2018\\E",
      "shortCiteRegEx" : "Ding et al\\.",
      "year" : 2018
    }, {
      "title" : "Erythrocyte membrane is an alternative coating to polyethylene glycol for prolonging the circulation lifetime of gold nanocages for photothermal therapy",
      "author" : [ "J.-G. Piao", "L. Wang", "F. Gao", "Y.-Z. You", "Y. Xiong", "L. Yang" ],
      "venue" : "ACS Nano,",
      "citeRegEx" : "Piao et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Piao et al\\.",
      "year" : 2014
    }, {
      "title" : "Venous thromboembolic disease and ABO blood type: a cooperative",
      "author" : [ "H. Jick", "B. Westerholm", "M. Vessey", "G. Lewis", "D. Slone", "W.W. Inman" ],
      "venue" : null,
      "citeRegEx" : "Jick et al\\.,? \\Q1969\\E",
      "shortCiteRegEx" : "Jick et al\\.",
      "year" : 1969
    }, {
      "title" : "Toxic potential of materials at the nanolevel",
      "author" : [ "A. Nel", "T. Xia", "L. Mädler", "N. Li" ],
      "venue" : null,
      "citeRegEx" : "Nel et al\\.,? \\Q2006\\E",
      "shortCiteRegEx" : "Nel et al\\.",
      "year" : 2006
    }, {
      "title" : "Core– shell supramolecular gelatin nanoparticles for adaptive and “on-demand” antibiotic delivery",
      "author" : [ "L.-L. Li", "J.-H. Xu", "G.-B. Qi", "X. Zhao", "F. Yu", "H. Wang" ],
      "venue" : "ACS Nano,",
      "citeRegEx" : "Li et al\\.,? \\Q2019\\E",
      "shortCiteRegEx" : "Li et al\\.",
      "year" : 2019
    } ],
    "referenceMentions" : [ ],
    "year" : 2019,
    "abstractText" : "The tumor variability and low efficiency associated with conventional chemical drugs provide an impetus to develop drug-carrying systems with targeted accumulation and controllable release behavior. Herein, DOX-loaded Prussian blue (PB) nano-composites are developed after coating with erythrocyte membrane (EM) and modifying with folic acid (FA). In these nano-composites, PB nanoparticles mixture with different shapes were adopted to improve the photothermal performance, which is highly helpful for cancer photothermal ablation and controllable drug release. In addition, the nano-composites were endowed with high biocompatibility, immune evading capacity, pH-/photo-responsive release behavior, and markedly prolonged blood circulation time, which was reflected by a 99.6% cervical tumor growth inhibition value (TGI) in vivo. Meanwhile, they functioned as multimodal bioimaging agents for photothermal, fluorescence, and photoacoustic imaging of tumors. The reported strategy can be applied for personalized therapy of various tumors by modifying the tumor-targeting molecule on the surface of nanoparticles.",
    "creator" : "Arbortext Advanced Print Publisher 9.1.510/W Unicode"
  }
}